Kymera COO Disposes $589,598 of Stock as Options Exercised Under 10b5-1 Plan
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick executed sales of 6,551 shares on April 14 and 15, 2026, generating roughly $589,598, and concurrently exercised options to acquire the same number of shares for about $225,436. The transactions were carried out under a Rule 10b5-1 plan adopted in December 2025. The stock has climbed su…